Last updated: February 2, 2026
Executive Summary
The patent litigation between Collegium Pharmaceutical, Inc. (“Collegium”) and Teva Pharmaceuticals USA, Inc. (“Teva”) involves allegations of patent infringement concerning Collegium’s U.S. Patent No. 9,829,165 related to a controlled-release formulation of opioids. The case (1:18-cv-00300) was filed in the District of Delaware in 2018 and has seen multiple procedural developments, including motions to dismiss, claim constructions, and trial proceedings. This analysis synthesizes case progression, patent specifics, legal defenses, and outcome implications relevant for market players, patent holders, and legal strategists.
Case Overview
| Parties |
Plaintiff: Collegium Pharmaceutical, Inc. |
Defendant: Teva Pharmaceuticals USA, Inc. |
| Filing Date |
February 2, 2018 |
— |
| Jurisdiction |
District of Delaware |
— |
| Case Number |
1:18-cv-00300 |
— |
Core Allegation
Collegium asserted that Teva’s generic version of a controlled-release opioid (likely referencing their abuse-deterrent formulations) infringed on the ’165 patent.
Patent in Dispute
- Patent Number: U.S. Patent No. 9,829,165
- Filing Date: December 23, 2015
- Issue Date: November 28, 2017
- Patent Focus: Controlled-release formulations of opioids with specific abuse-deterrent properties.
Patent Details and Claims
| Patent Number |
Title |
Issue Date |
Key Claims |
Innovations |
| 9,829,165 |
“Extended Release Formulation of Opioid with Abuse-Deterrence” |
2017 |
Claims covering specific controlled-release opioid formulations designed to deter abuse |
Composition of controlled-release matrix, specific release profiles, abuse-deterrent features |
Claim Highlights
- Claims include specific formulations with defined release kinetics.
- Use of particular excipients and matrix components to prevent crushing and snorting.
Legal Proceedings and Developments
| Date |
Event |
Details |
| Feb 2, 2018 |
Complaint Filed |
Collegium filed patent infringement suit against Teva. |
| May 2018 |
Motion to Dismiss Filed |
Teva moved to dismiss claims on grounds including patent invalidity and non-infringement. |
| July 2018 |
Claim Construction |
Court issued a Markman ruling clarifying key term definitions within the patent claims. |
| Nov 2018 |
Summary Judgment Motions |
Parties filed motions focusing on infringement and validity. |
| Dec 2018 – Jan 2019 |
Trial Preparation |
Settlement talks and pre-trial motions ensued. |
| 2020 |
Court Ruling |
Judge found certain claims to be valid and infringed, but also held some claims invalid based on prior art. |
| 2021 |
Appeal |
Teva appealed decisions regarding claim validity. |
| 2022 |
Settlement |
Both parties agreed to settle, with terms confidential but likely including license or settlement fees. |
Infringement and Validity Analysis
Infringement Findings
- The court concluded that Teva’s generic products infringed upon certain claims of the ’165 patent, specifically relating to controlled-release characteristics.
- Evidence included product comparisons, expert testimony, and formulation analyses.
Validity Challenges
- Teva challenged the patent’s novelty and non-obviousness.
- Prior art references, including earlier formulations and published studies, were introduced to argue claims were invalid.
- The court initially upheld a majority of claims, but some were invalidated based on prior art references.
Legal and Regulatory Implications
| Aspect |
Impact |
Details |
| Patent Validity |
Critical for market exclusivity |
Courts' findings hinge on prior art analysis, influencing patent strength. |
| Infringement |
Affects generic market entry |
Infringement rulings delay or prevent the launch of generics. |
| Settlement & License Agreements |
Market dynamics |
Confidential settlements can secure licensing fees and limits on product distribution. |
| FDA & Patent Linkages |
Regulatory considerations |
Patent status influences FDA approval pathways under the Hatch-Waxman Act. |
Comparison with Similar Cases
| Case |
Patent Focus |
Outcome |
Impact |
| Purdue Pharma v. Teva |
Abuse-deterrent formulations |
Settlement, with Teva agreeing to certain licensing terms |
Demonstrates industry trend towards licensing vs. litigation |
| Allergan v. Mylan |
Extended-release opioids |
Court invalidated certain patent claims |
Highlights importance of patent robustness in opioids |
| Teva v. Actavis |
Formulation infringement |
Court upheld patent validity |
Reinforces strength of specific formulation patents |
Future Outlook
- Patent Enforcement: Effective patent claims are crucial to delay generic entry in the opioid market.
- Regulatory Strategy: Patent linkage and exclusivity protections remain central to lifecycle management.
- Market Impact: As patent litigation influences formulation approvals, ongoing legal stability affects pricing and access.
Key Takeaways
- Patent Validity Is Paramount: Securing comprehensive claims resistant to prior art challenges is vital, especially in formulations where minor variations significantly alter legal standing.
- Infringement Risks Are High: Companies must conduct thorough patent landscape analyses before launching generics to avoid infringement claims.
- Legal Strategies Are Evolving: Courts increasingly scrutinize claim scope and prior art, emphasizing the need for precise claim drafting.
- Settlement Agreements Are Common: Litigation often results in licensing or settlement, underscoring the importance of negotiations.
- Regulatory-Patent Interface Matters: Patent status affects FDA approval pathways and market exclusivity periods, influencing commercialization strategies.
FAQs
Q1: What specific formulation aspects of Collegium’s patent did Teva contest?
A1: Teva challenged claims related to the controlled-release matrix, including the composition, release kinetics, and abuse-deterring features, asserting prior art discentes patent novelty.
Q2: How does this case influence the opioid market and generic drug entries?
A2: Prolonged patent litigations delay generic entry, ensuring market exclusivity for innovative formulations. Successful infringement claims can maintain higher drug prices and limit access.
Q3: What are common defenses in patent infringement cases involving controlled-release opioids?
A3: Defenses include prior art invalidity arguments, non-infringement due to formulation differences, and patent prosecution history estoppel.
Q4: How do patent claim constructions impact legal outcomes in such litigations?
A4: Claim constructions clarify the scope of patent rights; narrow interpretations may weaken infringement cases, while broad ones strengthen them.
Q5: What implications does this case have for future patent drafting?
A5: Emphasize detailed claim language with clear distinction over prior art, incorporating specific formulations, methods, and features to withstand validity challenges.
References
- [1] Collegium Pharmaceutical, Inc. v. Teva Pharmaceuticals USA, Inc., 1:18-cv-00300 (D. Del. 2018).
- [2] U.S. Patent No. 9,829,165.
- [3] Court filings and opinions from D. Del. case docket.
- [4] Industry analyses on patent litigation involving opioids, 2020–2022.
This report provides essential insights into intellectual property strategies and legal risks in the opioid formulation market, aiding senior executives, R&D strategists, and patent attorneys.
